Evidence map›Paper›PMID 23381789›Full record

ArticleHypertension (Dallas, Tex. : 1979)2013

Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism.

Vijaya Karoor, Masahiko Oka, Sandra J Walchak, Louis B Hersh, York E Miller, Edward C Dempsey

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse.Journal of visualized experiments : JoVE · 2018
    Article
  7. Article
  8. Article
  9. Review
  10. Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vijaya KaroorCardiovascular Pulmonary Research Laboratory, RC-2 Room 8118, University of Colorado Anschutz Medical Campus, 12700 E 19th Ave, RC-2, Aurora, CO 80045, USA. vijaya.karoor@ucdenver.edu
Masahiko Oka
Sandra J Walchak
Louis B Hersh
York E Miller
Edward C Dempsey
University of Kentucky · USUniversity of South Alabama · US

Funding

VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1M
Neprilysin Apoptosis and Hypoxic Pulmonary HypertensionR01HL078927 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI DEMPSEY, EDWARD CHARLES · 2005 to 2008
$1.5M
Selected Peptidases and Pulmonary Vascular Remodeling in Chronic Obstructive PulmR03HL095439 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI DEMPSEY, EDWARD CHARLES · 2008 to 2009
$154k
NHLBI NIH HHS HL014985NHLBI NIH HHS HL078927NHLBI NIH HHS HL095439NHLBI NIH HHS P01 HL014985NHLBI NIH HHS R01 HL078927NHLBI NIH HHS R03 HL095439
6 · The paper itself

Abstract

Reduced neprilysin (NEP), a cell surface metallopeptidase, which cleaves and inactivates proinflammatory and vasoactive peptides, predisposes the lung vasculature to exaggerated remodeling in response to hypoxia. We hypothesize that loss of NEP in pulmonary artery smooth muscle cells results in increased migration and proliferation. Pulmonary artery smooth muscle cells isolated from NEP(-/-) mice exhibited enhanced migration and proliferation in response to serum and platelet-derived growth factor, which was attenuated by NEP replacement. Inhibition of NEP by overexpression of a peptidase dead mutant or knockdown by small interfering RNA in NEP(+/+) cells increased migration and proliferation. Loss of NEP led to an increase in Src kinase activity and phosphorylation of PTEN, resulting in activation of the platelet-derived growth factor receptor (PDGFR). Knockdown of Src kinase with small interfering RNA or inhibition with PP2, a src kinase inhibitor, decreased PDGFR(Y751) phosphorylation and attenuated migration and proliferation in NEP(-/-) smooth muscle cells. NEP substrates, endothelin 1 or fibroblast growth factor 2, increased activation of Src and PDGFR in NEP(+/+) cells, which was decreased by an endothelin A receptor antagonist, neutralizing antibody to fibroblast growth factor 2 and Src inhibitor. Similar to the observations in pulmonary artery smooth muscle cells, levels of phosphorylated PDGFR, Src, and PTEN were elevated in NEP(-/-) lungs. Endothelin A receptor antagonist also attenuated the enhanced responses in NEP(-/-) pulmonary artery smooth muscle cells and lungs. Taken together our results suggest a novel mechanism for the regulation of PDGFR signaling by NEP substrates involving Src and PTEN. Strategies that increase lung NEP activity/expression or target key downstream effectors, like Src, PTEN, or PDGFR, may be of therapeutic benefit in pulmonary vascular disease.

Indexed as

AnimalsDisease Models, AnimalHypertension, PulmonaryMiceMice, Inbred C57BLMuscle, Smooth, VascularNeprilysinPhenotypePulmonary ArteryReceptor, Platelet-Derived Growth Factor betaSignal TransductionNeprilysinReceptor, Platelet-Derived Growth Factor beta

Identifiers

PMID23381789
PMCPMC3667616
OpenAlexW2120801774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.